Integrated Biopharma annual operating margin
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Integrated Biopharma's operating margin was 3.72% for fiscal 2025.
View full Integrated Biopharma company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-06-30 | 3.72% | +3.22 pp |
| 2024 | 2024-06-30 | 0.50% | +0.26 pp |
| 2023 | 2023-06-30 | 0.24% | −4.64 pp |
| 2022 | 2022-06-30 | 4.88% | −4.22 pp |
| 2021 | 2021-06-30 | 9.10% | +2.92 pp |
| 2020 | 2020-06-30 | 6.18% | +0.77 pp |
| 2019 | 2019-06-30 | 5.41% | +1.53 pp |
| 2018 | 2018-06-30 | 3.88% | −2.91 pp |
| 2017 | 2017-06-30 | 6.79% | +1.78 pp |
| 2016 | 2016-06-30 | 5.01% | +2.52 pp |
| 2015 | 2015-06-30 | 2.49% | −1.53 pp |
| 2014 | 2014-06-30 | 4.01% | +0.69 pp |
| 2013 | 2013-06-30 | 3.32% | +4.70 pp |
| 2012 | 2012-06-30 | −1.38% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q3 2026 | 2026-03-31 | −10.74% | −16.03 pp |
| Q2 2026 | 2025-12-31 | −8.10% | −9.70 pp |
| Q1 2026 | 2025-09-30 | 1.28% | −2.31 pp |
| Q4 2025 | 2025-06-30 | 4.16% | +1.00 pp |
| Q3 2025 | 2025-03-31 | 5.30% | +2.60 pp |
| Q2 2025 | 2024-12-31 | 1.60% | +5.53 pp |
| Q1 2025 | 2024-09-30 | 3.60% | +4.02 pp |
| Q4 2024 | 2024-06-30 | 3.15% | +2.55 pp |
| Q3 2024 | 2024-03-31 | 2.70% | +2.36 pp |
| Q2 2024 | 2023-12-31 | −3.93% | −3.66 pp |
| Q1 2024 | 2023-09-30 | −0.42% | −0.66 pp |
| Q4 2023 | 2023-06-30 | 0.61% | −2.69 pp |
| Q3 2023 | 2023-03-31 | 0.34% | −6.01 pp |
| Q2 2023 | 2022-12-31 | −0.27% | −5.27 pp |
| Q1 2023 | 2022-09-30 | 0.24% | −4.34 pp |
| Q4 2022 | 2022-06-30 | 3.30% | −4.39 pp |
| Q3 2022 | 2022-03-31 | 6.35% | −3.72 pp |
| Q2 2022 | 2021-12-31 | 5.00% | −3.72 pp |
| Q1 2022 | 2021-09-30 | 4.59% | −5.36 pp |
| Q4 2021 | 2021-06-30 | 7.69% | +3.13 pp |
| Q3 2021 | 2021-03-31 | 10.07% | +3.03 pp |
| Q2 2021 | 2020-12-31 | 8.73% | +0.24 pp |
| Q1 2021 | 2020-09-30 | 9.95% | +5.77 pp |
| Q4 2020 | 2020-06-30 | 4.57% | +0.33 pp |
| Q3 2020 | 2020-03-31 | 7.04% | −1.74 pp |
| Q2 2020 | 2019-12-31 | 8.49% | +4.43 pp |
| Q1 2020 | 2019-09-30 | 4.17% | +0.24 pp |
| Q4 2019 | 2019-06-30 | 4.23% | −0.74 pp |
| Q3 2019 | 2019-03-31 | 8.78% | +2.54 pp |
| Q2 2019 | 2018-12-31 | 4.06% | +2.22 pp |
| Q1 2019 | 2018-09-30 | 3.93% | +1.77 pp |
| Q4 2018 | 2018-06-30 | 4.97% | −2.40 pp |
| Q3 2018 | 2018-03-31 | 6.24% | +2.21 pp |
| Q2 2018 | 2017-12-31 | 1.83% | −2.77 pp |
| Q1 2018 | 2017-09-30 | 2.16% | −8.56 pp |
| Q4 2017 | 2017-06-30 | 7.37% | −1.51 pp |
| Q3 2017 | 2017-03-31 | 4.03% | −0.08 pp |
| Q2 2017 | 2016-12-31 | 4.61% | +2.99 pp |
| Q1 2017 | 2016-09-30 | 10.72% | +5.58 pp |
| Q4 2016 | 2016-06-30 | 8.88% | +8.06 pp |
| Q3 2016 | 2016-03-31 | 4.10% | +3.98 pp |
| Q2 2016 | 2015-12-31 | 1.61% | −2.26 pp |
| Q1 2016 | 2015-09-30 | 5.13% | −0.10 pp |
| Q4 2015 | 2015-06-30 | 0.82% | −2.47 pp |
| Q3 2015 | 2015-03-31 | 0.12% | +2.73 pp |
| Q2 2015 | 2014-12-31 | 3.88% | −3.17 pp |
| Q1 2015 | 2014-09-30 | 5.23% | −1.95 pp |
| Q4 2014 | 2014-06-30 | 3.29% | −1.06 pp |
| Q3 2014 | 2014-03-31 | −2.61% | — |
| Q2 2014 | 2013-12-31 | 7.04% | — |
| Q1 2014 | 2013-09-30 | 7.18% | — |
| Q1 2013 | 2012-09-30 | 4.35% | — |
Over the last five reported fiscal years, Integrated Biopharma's operating margin decreased from 6.18% to 3.72%, a change of −2.46 percentage points. The latest reported quarter, Q3 2026, shows −10.74%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Integrated Biopharma filings at SEC.gov ↗